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OBJECTIVES: To analyze use of anti-infective drugs for systemic administration
(ATC-group J) in Serbia in 2010 year. METHODS: Data about use of anti-infective
drugs for systemic administration in Serbia in 2010 was taken from the Agency for
Drugs and Medical Devices of Serbia. RESULTS: Total use of all drugs in Serbia in
2010 was 966,26 DDD/1000 inhabitants/day. ATC-group J was on the eighth place
according to amount of DDDs with 19,63 DDD/1000 inh/day or 2,03% of total con-
sumption. According to the funding spent, this group was on the second position
with 90.651.670,00€. In this group, subgroup with highest consumption were anti-
bacterial drugs for systemic use (subgroup J01), with 19,35 DDD/1000 inh/day or
98,57% of total use in group J. This subgroup takes first place in funding spent with
59.740.274,49€ or 65,90% of total expended finances in this group in 2010. Beta-
lactam antibacterial drugs with 11,71 DDD/1000 inh/day or 60,52%were drugs with
highest use in this subgroup, macrolides and lincosamides were at second place
with 3,23 DDD/1000 inh/day or 16,69%, while on the third place were quinolones
with 2,09 DDD/1000 inh/day or 10,80% of total drug utilization inside this subgroup.
Funding spent on beta-lactam antibacterial drugs was 36.469.664,56€ or 61,05%,
macrolides and lincosamides 8.573.022,83€ or 14,35%, and for quinolones
6.745.763,79€ or 11,29% of total funding spent for subgroup J01 in the year 2010.
CONCLUSIONS: In comparison to 2009 spending of group J in Serbia in 2010 year
was decreased for 18,35 DDD/1000 inh/day or 48,31%. The amount of funding spent
in this group, however, of drugs was decreased for only 20,03%.
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OBJECTIVES: To estimate the prevalence of potential interactions between anti-
platelet drugs, anticoagulants, digoxin and Chinese medications (CM) and further
to explore the determining factors associated with the occurrence of potential
interactions. METHODS: This study assessed the prevalence of exposure to the
major interactions between the seven selected western medications commonly
used for the cardiovascular diseases (i.e., aspirin, clopidogrel, digoxin, dipyridam-
ole, heparin, ticlopidine, and warfarin [in terms of high risk western medications,
HRWM]) and selected common used CM (i.e., American ginseng, Asian ginseng,
danshen, and dong quai), using the two-million National Health Insurance (NHI)
Research Database in Taiwan. Both univariate and multivariate logistic regression
analyses were conducted to identify the contributing factors (e.g., baseline demo-
graphics, comorbidities, health services utilizations) of potential major interac-
tions incidence. RESULTS: While 14.7% of HRWM users (19,431/131,804) ever used
those selected CM concurrently at anytime in 2007, 81.9% (15,919/19,431) of
HRWM-CM concurrent users had been exposed to at least one combination of
potentialmajor interactions. Anticoagulants (i.e., heparin andwarfarin) userswere
more likely to be prescribed with the selected CM with major interactions (86.7%
and 86%, respectively). The concomitant use of aspirinwith dong quai or Asian ginseng
wasmore prevalent than others. The factors that statistically significantly associated
with the incremental exposure of potential major interactions included female sex,
age 45-84 years old, higher number of outpatient visits, distinct medications pre-
scribed, and previous diagnosis of stroke. In contrast, those HRWM-CM users with
high monthly income, enrolled in the West region of Taiwan NHI, and had previous
history of acute respiratory infection were less likely to exposure to the major inter-
actions of HRWM-CM use. CONCLUSIONS: The exposure of the major interactions
with CMwas relative prevalent among HRWMusers in Taiwan. Further research is
needed to investigate the outcomes associated with such combinations.
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OBJECTIVES: Toexamine theprospective associationbetweenperceptionofhealthdur-
ing pregnancy and cardiovascular risk factor of mothers 21 years after the index
pregnancy.METHODS: Data used were from the Mater University Study of Pregnancy
(MUSP), a community- basedprospective birth cohort studybegun inBrisbane,Australia,
in 1983. Logistic regression analyses were conducted. RESULTS: Data were available for
3692 women.Womenwho perceived themselves as not having a straight forward preg-
nancy had twice the odds (adjusted OR 2.0, 95% CI 1.1-3.8) of being diagnosedwith heart
disease21yearsafter the indexpregnancyascomparedtowomenwithastraight forward
pregnancy. Apart from that, women who had complications (other than serious preg-
nancycomplications)during thepregnancywerealsoat30%increasedodds (adjustedOR
1.3, 95% CI 1.0-1.6) of having hypertension 21 years later. CONCLUSIONS: As a whole,
our study suggests that pregnant women who perceived that they had complica-
tions and did not have a straight forward pregnancy are likely to experience poorer
cardiovascular outcomes 21 years after the pregnancy.
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OBJECTIVES: There were more than 200 million hypertension (HTN) patients in
China. Uncontrolled HTN results in strokes, myocardial infarction (MI) and other
complications, which are the leading cause of disability, death and severe eco-
nomic consequence.We conducted an economic evaluation to determine the costs
and quality-adjusted life years (QALYs) associated with Amlodipine (Norvasc) and
the Angiotensin II Receptor Blockers (ARBs) in preventing stroke and MI among
Chinese HTN patients.METHODS: A cost-utility analysis was conducted from the
third-party payer perspective. A Markov model was constructed to estimate five
year costs and health consequences (12-month cycles). For each arm, 10,000 pa-
tients were included for the simulation with Valsartan as comparator. Effective-
ness data on incidence of stroke and MI were based on a published meta-analysis.
Relative risks of stroke andMI were 0.84 and 0.83 respectively comparing Amlodip-
ine and ARBs. Utility data were retrieved from the published literature. Costs of MI
were retrieved fromChinese government reimbursement database. Costs of stroke
were obtained from retrospective chart review and follow-up interviews in Chinese
tertiary hospitals. Costs included costs of drugs, direct medical costs of hyperten-
sion management, stroke/MI treatment, and follow-up management. Discounting
rate used for costs and QALYs was 3%. RESULTS: Total direct medical and drug
costs of Amlodipine and Valsartan users are ¥111,731,716 and ¥132,058,611 respec-
tively; total QALYs of Amlodipine and Valsartan users are 30,648.5 and 30,520.8,
respectively. Amlodipine is dominant with lower costs and higher QALYs. This
demonstrated that, compared with Valsartan, Amlodipine is a cost saving therapy
with increased overall survival due to the reduction in stroke andMI events. When
Ibersartan data were used in the comparison, the magnitude of cost saving
changed but overall conclusion remained the same. CONCLUSIONS: Amolodipine
is a cost saving therapy compared with ARBs in preventing stroke and MI for Chi-
nese hypertension patients.
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OBJECTIVES: To examine a cohort of patients with all forms of cardiac arrhythmia
(CA) and identify factors associated with cost of care, health care resource utiliza-
tion, antiarrhythmic agent use, and quality of life. METHODS: This retrospective
database analysis utilized the household component data from 2004 to 2009
Agency for Healthcare Research and Quality Medical Panel Expenditure Survey.
Patients aged  18 and had any form of CA (identified via ICD-9-CM codes 427.0-
427.2, 427.31-427.32, 427.60-427.61, 427.69, 427.81, 427.89, 427.9, 785.0-785.1) were
included. Primary independent variables of interest included age, gender, race/
ethnicity, and pharmacotherapy use. Total annual health care expenditure, total
annual prescribed medicine expenditure, physical and mental component sum-
mary scores (PCS and MCS) of the Short-Form 12 version 2 (SF-12), EuroQoL-5D
(EQ-5D) utility scores (US version), proportion of patients using antiarrhythmic
medications, number of prescribed medications associated with their cardiac ar-
rhythmia, and proportion of patients with inpatient, outpatient, or emergency
room visits were the primary outcomes of interest. Multivariate ordinary least
squares (OLS) and generalized linear models (GLM) were used to analyze factors
related to the aforementioned outcomes. To provide national estimates, all results
were weighted and used standard errors (SE) calculated via Taylor-series
approaches. RESULTS: Annually, 5,750,440 non-institutionalized US persons were
estimated to suffer from cardiac arrhythmia between 2004 and 2009. Higher health
care expenditure and utilization appeared in non-Hispanic whites and patients
aged 65 (p0.05). As compared tomale patients, females had significantly higher
prescribed medication expenditure, lower proportion of inpatient and emergency
department visits related to arrhythmia, and lower PCS score (p0.05). Patients on
antiarrhythmics had significantly higher health care expenditures, lower propor-
tion of emergency department visits related to arrhythmia, and higher MCS score
(p0.05) compared with their counterparts. CONCLUSIONS: Potential health dis-
parities exist across age, gender, race, and antiarrhythmic use among CA patients.
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OBJECTIVES: Venous thromboembolism(VTE), a condition that includes deep vein
thrombosis(DVT) and pulmonary embolism(PE) is associated withmajormorbidity
andmortality and causes huge economic burden. The objective of this analysiswas
to determine the hospitalization costs and their predictors due to DVT/PE in China.
METHODS: A total of 278 patients with DVT or PE were randomly selected by
stratified two-stage sampling from the China BasicMedical Insurance Databases in
2009 and 2010. All information of patient demographic characters, length of stay,
clinical and costs were collected for the analysis. The descriptive statistics was
used to describe patients’ demographic characters, the hospital stay and the hos-
pital costs. Univariate and multivariable analyses were also used in the data
analysis. RESULTS: Total 278 patients (mean age 64.4 years; 58.3% male) were
evaluated, 61.9% of patients with DVT and 38.1% of patients with PE. The mean
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